Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With a History of Frequent Exacerbations
← catalyst calendarSponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 3
Status
Completed
Study type
Interventional
Design
Randomized · Triple · Treatment
Enrollment
689actual
Sites
343
Countries
Argentina, Australia, Austria +27
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2019-08-26 | actual | When the study began enrolling |
| Primary completion | 2025-07-28 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-07-28 | actual | The whole study's end, after follow-up |
| First posted | 2019-08-12 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-08-19 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Chronic Obstructive Pulmonary Disease
Interventions
- Biological: Benralizumab
- Biological: Placebo
Primary outcome
what the primary-completion date above is the date OFAnnualized rate of moderate or severe COPD exacerbations
measured Over first 56 weeks
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed